Rocket Lab enters the first week of June having shed 14% from its recent highs, with C-suite selling continuing and short interest quietly rebuilding — a shift from the covering-driven narrative that dominated May.
The most concrete development is what insiders did on May 28. COO Frank Klein sold more than 30,000 shares across multiple tranches, collecting roughly $4.5 million at prices between $143 and $150. General Counsel Arjun Kampani sold a further 8,110 shares for around $1.2 million at similar levels. Combined, that's nearly $5.7 million in insider disposals in a single session — following the $17 million-plus of C-suite sales flagged in the previous note covering May 26-27. The 90-day net figure has now compressed to roughly $36.8 million positive, a number inflated by Peter Beck's reported 5-million-share addition to the institutional register. Strip that out and the picture is a consistent stream of senior management exits into the rally. These are orderly, planned sales rather than panic — but the volume and clustering just below the recent $155 peak is a pattern worth tracking into August earnings.
Short interest has stopped falling and nudged higher. At 5.8% of the free float, it has risen roughly 6% on the week after touching a five-week low on May 26. That reversal is small but marks the first sustained uptick since early May's peak near 6.4%. Availability remains extremely loose at 1,486% — nearly fifteen shares in the lending pool for every one borrowed — and borrowing costs are negligible at 0.45%. There is no mechanical squeeze pressure here. The modest rise in short interest looks more like fresh positioning at lower prices than trapped shorts unable to exit. The ORTEX short score has eased to 38.7, near the bottom of its recent range, suggesting the overall short-seller setup remains undemanding rather than extreme.
Options traders have stepped back from the defensive posture of last week. The put/call ratio has pulled back to 0.78, now slightly below its 20-day average of 0.80 — a mild improvement from the elevated readings of late May when the ratio approached 0.84. The z-score at -0.67 puts current positioning modestly below average on the put-demand spectrum. That is a quiet reversal of the caution flagged in the prior note. Call-side activity is marginally more active relative to puts, suggesting the 14% weekly drawdown has not dramatically changed options sentiment in either direction.
The stock's EPS surprise rank is in the 92nd percentile of the universe — a reflection of the Q1 beat that launched the post-earnings rally. Forward EPS estimates are improving at a rate that ranks in the 63rd percentile year-on-year. On valuation, the price-to-book has compressed to 41.5x from above 50x at the rally peak, while the EV/EBITDA at 4,499x remains economically irrelevant as a current metric — this is a growth-priced name where revenue trajectory matters far more than current earnings multiples. Among the closest correlated peers, LUNR gained 13.5% on the week and MRCY added 13.6%, both holding up better than RKLB's -13.9%. FLY saw the sharpest divergence, falling 26%.
The setup into August 6 earnings is the key watch. The stock is down 14% from its intra-week high but still up 56% over the past month. Whether the C-suite selling accelerates, stalls, or reverses near current levels will be as informative as any datapoint ahead of the next print.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
